A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)".
作者信息
Attal Sepideh
机构信息
Pfizer PIO, 23-25 Avenue du Dr Lannelongue, 75668, Paris Cedex 14, France.
出版信息
Cardiol Ther. 2024 Dec;13(4):815-817. doi: 10.1007/s40119-024-00383-4. Epub 2024 Oct 23.
Abstract
摘要
相似文献
1
A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)".
Cardiol Ther. 2024 Dec;13(4):815-817. doi: 10.1007/s40119-024-00383-4. Epub 2024 Oct 23.
2
Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)'.
Cardiol Ther. 2024 Dec;13(4):811-814. doi: 10.1007/s40119-024-00382-5. Epub 2024 Oct 23.
3
Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).
Cardiol Ther. 2024 Jun;13(2):369-378. doi: 10.1007/s40119-024-00365-6. Epub 2024 Apr 13.
4
German longitudinal prescription database (LRx): Description of characteristics, use in pharmacoepidemiological research, and limitations
.
Int J Clin Pharmacol Ther. 2024 Jan;62(1):20-28. doi: 10.5414/CP204485.
5
Influenza vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: a secondary data analysis based on billing data of the German associations of statutory health insurance physicians.
Dtsch Arztebl Int. 2010 Dec;107(48):845-50. doi: 10.3238/arztebl.2010.0845. Epub 2010 Dec 3.
6
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort.
J Manag Care Spec Pharm. 2022 Jul;28(7):766-777. doi: 10.18553/jmcp.2022.28.7.766.
7
[Compilation of Second Opinion Programs in the German Statutory Health Insurance].
Gesundheitswesen. 2018 Oct;80(10):859-863. doi: 10.1055/s-0043-105576. Epub 2017 May 15.
8
[The German Statutory Accident Insurance: A successful example of a value-based healthcare structure].
Z Evid Fortbild Qual Gesundhwes. 2018 Feb;130:13-20. doi: 10.1016/j.zefq.2017.07.009. Epub 2017 Sep 1.
9
Analysis of second opinion programs provided by German statutory and private health insurance - a survey of statutory and private health insurers.
BMC Health Serv Res. 2021 Mar 9;21(1):209. doi: 10.1186/s12913-021-06207-8.
10
Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany.
Eur J Clin Pharmacol. 2024 Jun;80(6):931-940. doi: 10.1007/s00228-024-03654-0. Epub 2024 Mar 12.
本文引用的文献
1
Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)'.
Cardiol Ther. 2024 Dec;13(4):811-814. doi: 10.1007/s40119-024-00382-5. Epub 2024 Oct 23.
2
Anticoagulation in Atrial Fibrillation Associated With Cardiac Amyloidosis: A Narrative Review.
Cureus. 2024 Jun 3;16(6):e61557. doi: 10.7759/cureus.61557. eCollection 2024 Jun.
3
Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis.
J Clin Med. 2024 Apr 12;13(8):2257. doi: 10.3390/jcm13082257.
4
Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).
Cardiol Ther. 2024 Jun;13(2):369-378. doi: 10.1007/s40119-024-00365-6. Epub 2024 Apr 13.
5
Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis.
Int J Cardiol. 2024 May 1;402:131813. doi: 10.1016/j.ijcard.2024.131813. Epub 2024 Jan 24.
6
Conventional heart failure therapy in cardiac ATTR amyloidosis.
Eur Heart J. 2023 Aug 14;44(31):2893-2907. doi: 10.1093/eurheartj/ehad347.
7
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.
Circulation. 2022 Nov 29;146(22):1657-1670. doi: 10.1161/CIRCULATIONAHA.122.060852. Epub 2022 Nov 3.
8
Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.
J Clin Med. 2022 Apr 12;11(8):2148. doi: 10.3390/jcm11082148.
9
Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy.
Mayo Clin Proc. 2022 Feb;97(2):261-273. doi: 10.1016/j.mayocp.2021.08.006. Epub 2021 Nov 19.
10
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur J Heart Fail. 2021 Apr;23(4):512-526. doi: 10.1002/ejhf.2140. Epub 2021 Apr 7.
Zotero 插件